PMID: 11920601Mar 29, 2002Paper

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells

International Journal of Cancer. Journal International Du Cancer
F CiardielloG Tortora

Abstract

Constitutive bcl-2 overexpression increases the tumorigenic and metastatic potential of doxorubicin-resistant, estrogen-independent, MCF-7 ADR human breast cancer cells. We evaluated the sensitivity to taxanes (paclitaxel, docetaxel and IDN 5109) of 2 bcl-2-overexpressing MCF-7 ADR clones and control neomycin-transfected MCF-7 ADR neo cells. The 2 bcl-2-overexpressing MCF-7 ADR clones were relatively resistant to all 3 taxanes, whereas the MCF-7 ADR neo cells were relatively resistant to paclitaxel and docetaxel, but sensitive to IDN 5109. We found that both MCF-7 ADR neo and bcl-2-overexpressing MCF-7 ADR clones express high levels of the epidermal growth factor receptor (EGFR) and its ligand, transforming growth factor-alpha (TGF-alpha). Therefore, we tested the growth inhibitory effect of ZD1839 (Iressa, AstraZeneca, Macclesfield, UK), an orally active, selective EGFR tyrosine kinase inhibitor (EGFR-TKI) that is in clinical development. ZD1839 inhibited the growth in soft agar of all 3 clones in a dose-dependent manner (IC(50) of approximately 0.1 microm). This effect was accompanied by a dose-dependent inhibition of EGFR tyrosine autophosphorylation and of the production of TGF-alpha, basic fibroblast growth factor (bFGF) a...Continue Reading

References

Jul 1, 1995·Critical Reviews in Oncology/hematology·D S SalomonN Normanno
Aug 18, 1993·Journal of the National Cancer Institute·J BaselgaJ Mendelsohn
Mar 5, 1997·Journal of the National Cancer Institute·J Mendelsohn, Z Fan
Oct 23, 1997·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D Del BufaloG Zupi
Aug 24, 1999·Pharmacology & Therapeutics·J R Woodburn
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C Reed
Apr 1, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A BiroccioD Del Bufalo
Oct 12, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L J Burke, A Baniahmad

❮ Previous
Next ❯

Citations

Sep 2, 2006·Journal of Mammary Gland Biology and Neoplasia·Samuel K ChanWilliam J Gullick
Nov 10, 2009·Archives of Pharmacal Research·Dong-Oh MoonGi-Young Kim
Apr 3, 2004·Cancer Treatment Reviews·Sufi Mary Thomas, Jennifer Rubin Grandis
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Alicia M Viloria-Petit, Robert S Kerbel
Jun 16, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takeshi KitazakiShigeru Kohno
Nov 13, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Neal E Ready, Everett E Vokes
Apr 9, 2009·Pharmacogenetics and Genomics·Soo-Chin LeeBoon-Cher Goh
Mar 25, 2006·Future Oncology·Fortunato Ciardiello
Feb 5, 2014·Cancer Chemotherapy and Pharmacology·Antonia KalykakiVassilis Georgoulias
Jun 5, 2003·Expert Opinion on Investigational Drugs·Rita NahtaFrancisco J Esteva
Dec 10, 2003·Expert Opinion on Emerging Drugs·Fortunato CiardielloGiampaolo Tortora
May 31, 2002·Expert Opinion on Investigational Drugs·Fortunato Ciardiello, Giampaolo Tortora
Feb 19, 2010·Expert Opinion on Drug Metabolism & Toxicology·Sing-Huang Tan, Soo-Chin Lee
Feb 22, 2005·Neoplasia : an International Journal for Oncology Research·Zhiwen Liu, Julius Klominek
Jan 23, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jen-Chung KoYun-Wei Lin
Oct 22, 2008·Gynecologic Oncology·Izabela Ziółkowska-SetaJolanta Kupryjańczyk
Aug 4, 2007·Cancer Detection and Prevention·Agnieszka H LudwigJolanta Kupryjańczyk
Jan 10, 2009·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Michiyo MiyawakiMasatsugu Moriyama
Oct 13, 2006·International Journal of Cancer. Journal International Du Cancer·Daisuke TakabatakeHiroyoshi Doihara
Apr 27, 2007·Journal of Cellular Physiology·Marco RosettiRosella Silvestrini
Feb 14, 2006·International Journal of Cancer. Journal International Du Cancer·Marie P PiechockiFulvio Lonardo
Dec 28, 2004·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·G Milano, N Magné
Jun 9, 2004·Critical Reviews in Oncology/hematology·Jyoti D PatelAthanassios Argiris
Nov 29, 2015·Seminars in Oncology·Keara L RedmondSandra Van Schaeybroeck
Mar 1, 2005·Respiratory Medicine·Martin Reck, Ulrich Gatzemeier
Jul 11, 2006·Critical Reviews in Oncology/hematology·Claudia María ValverdeJosep Tabernero
May 14, 2005·Critical Reviews in Oncology/hematology·Andrea Mancuso, Cora N Sternberg
Mar 15, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Giovanni AlmadoriMaurizio Maurizi
Nov 6, 2018·Journal of Gastroenterology and Hepatology·Kai SongZheng Guo
Dec 18, 2004·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Tadahiko ShienNobuyoshi Shimizu
Jul 2, 2011·Molecular Biology Reports·Ozlem Darcansoy IşeriUfuk Gündüz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.